Clin Infect Dis

1. HASAN T, Lynch M, King C, Wehbe C, et al
   Vaccine-Preventable Disease Outbreaks among Healthcare Workers: A Scoping Review.
   Clin Infect Dis. 2024 Apr 17:ciae209. doi: 10.1093.
   

   >> Share

   
   
2. 
   Correction to: Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients.
   Clin Infect Dis. 2024 Apr 15:ciae165. doi: 10.1093.
   

   >> Share

   
   

   
   J Infect Dis

3. 
   Correction to: Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
   J Infect Dis. 2024 Apr 18:jiae186. doi: 10.1093.
   

   >> Share

   
   
4. NIKITIN D, Whittles LK, Imai-Eaton JW, White PJ, et al
   Cost-effectiveness of 4CMenB vaccination against gonorrhea: importance of dosing schedule, vaccine sentiment, targeting strategy, and duration of protection.
   J Infect Dis. 2024 Apr 17:jiae123. doi: 10.1093.
   

   >> Share

   
   
5. COHEN MS, Marrazzo J
   What if We Had a Vaccine that Prevents Neisseria gonorrhoeae.
   J Infect Dis. 2024 Apr 17:jiae160. doi: 10.1093.
   

   >> Share

   
   
6. UZZELL CB, Abraham D, Rigby J, Troman CM, et al
   Environmental Surveillance for Salmonella Typhi and its Association With Typhoid Fever Incidence in India and Malawi.
   J Infect Dis. 2024;229:979-987.
   

   >> Share

   
   
7. SCHMIDT S, Mengistu M, Daffis S, Ahmadi-Erber S, et al
   Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus-Specific CD8 T-Cell Responses and High Anti-Hepatitis B Surface Antigen Titers.
   J Infect Dis. 2024;229:1077-1087.
   

   >> Share

   
   
8. THOMPSON KM, Kalkowska DA, Routh JA, Brenner IR, et al
   Modeling Poliovirus Transmission and Responses in New York State.
   J Infect Dis. 2024;229:1097-1106.
   

   >> Share

   
   

   
   J Virol

9. FAN Y-C, Chen J-M, Chen Y-Y, Ke Y-D, et al
   Epitope(s) involving amino acids of the fusion loop of Japanese encephalitis virus envelope protein is(are) important to elicit protective immunity.
   J Virol. 2024;98:e0177323.
   

   >> Share

   
   

   
   MMWR Morb Mortal Wkly Rep

10. COLLINS JP, Crowe SJ, Ortega-Sanchez IR, Bahta L, et al
    Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged >/=10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:345-350.
    

    >> Share

    
    
11. ZAMBRANO LD, Newhams MM, Simeone RM, Payne AB, et al
    Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents - United States, 2021-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:330-338.
    

    >> Share

    
    
12. FRANKLIN D, Barbre K, Rowe TA, Reses HE, et al
    COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19-Associated Hospitalization Among Residents in Nursing Homes - National Healthcare Safety Network, United States, October 2023-February 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:339-344.
    

    >> Share

    
    
13. MATHIS AD, Raines K, Masters NB, Filardo TD, et al
    Measles - United States, January 1, 2020-March 28, 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:295-300.
    

    >> Share

    
    

    
    Nat Med

14. SARAF A, Gurjar R, Kaviraj S, Kulkarni A, et al
    An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.
    Nat Med. 2024 Apr 18. doi: 10.1038/s41591-024-02955.
    

    >> Share

    
    

    
    Pediatrics

15. MCKEITHEN MC, Gilkey MB, Kong WY, Oh NL, et al
    Policy Approaches for Increasing Adolescent HPV Vaccination Coverage: A Systematic Review.
    Pediatrics. 2024 Apr 16:e2023064692. doi: 10.1542/peds.2023-064692.
    

    >> Share

    
    

    
    PLoS Med

16. JUNG SM, Loo SL, Howerton E, Contamin L, et al
    Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub.
    PLoS Med. 2024;21:e1004387.
    

    >> Share

    
    

    
    PLoS One

17. RAZAI MS, Mansour R, Ravindran P, Freeman S, et al
    Facilitators and barriers to vaccination uptake in pregnancy: A qualitative systematic review.
    PLoS One. 2024;19:e0298407.
    

    >> Share

    
    
18. HOSSAIN FB, Jayasinghe S, Blazek K, He WQ, et al
    Pneumococcal vaccination and primary care presentations for acute respiratory tract infection and antibiotic prescribing in older adults.
    PLoS One. 2024;19:e0299924.
    

    >> Share

    
    
19. ZHANG Q, Tiwari S, Wen J, Wang S, et al
    Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains in mice.
    PLoS One. 2024;19:e0300524.
    

    >> Share

    
    
20. RENEER ZB, Bergeron HC, Reynolds S, Thornhill-Wadolowski E, et al
    mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge.
    PLoS One. 2024;19:e0297833.
    

    >> Share

    
    
21. BADE V, Schmitz H, Tawiah BB
    Regional variations in vaccination against COVID-19 in Germany.
    PLoS One. 2024;19:e0296976.
    

    >> Share

    
    
22. SANVEE-BLEBO LM, Adewuyi PA, Whesseh FK, Babalola OJ, et al
    COVID-19 vaccine hesitancy among adults in Liberia, April-May 2021.
    PLoS One. 2024;19:e0297089.
    

    >> Share

    
    
23. ZAID SNA, Abdul Kadir A, Mohd Noor N, Ahmad B, et al
    Translation and trans-cultural adaptation to the Malay version of the COVID-19 vaccine hesitancy questionnaire among healthcare workers in Malaysia.
    PLoS One. 2024;19:e0302237.
    

    >> Share

    
    
24. LERDSAMRAN H, Anusorntanawat R, Sangsiriwut K, Sawadpongpan S, et al
    Higher correlation between neutralizing antibodies and surrogate neutralizing or binding antibodies in COVID-19 patients than vaccine recipients.
    PLoS One. 2024;19:e0298033.
    

    >> Share

    
    
25. TAN H, Liu J, Zhang Y
    Effects of COVID-19 vaccine safety framing on parental reactions.
    PLoS One. 2024;19:e0302233.
    

    >> Share

    
    
26. MARQUEZ-MARTINEZ S, Salisch N, Serroyen J, Zahn R, et al
    Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses.
    PLoS One. 2024;19:e0299215.
    

    >> Share

    
    
27. THIELMANN A, Schmitz MT, Welchowski T, Weltermann B, et al
    Effectiveness of the online-eLearning program KeepCoool at improving the vaccine cold chain in general practices.
    PLoS One. 2024;19:e0301847.
    

    >> Share

    
    
28. KYAKUWA N, Kimbugwe G, Nakanjako F, Kalute H, et al
    High uptake of COVID-19 vaccines among healthcare workers in urban Uganda.
    PLoS One. 2024;19:e0277072.
    

    >> Share

    
    
29. LIN L, Demirhan H, P Johnstone-Robertson S, Lal R, et al
    Assessing the impact of Australia's mass vaccination campaigns over the Delta and Omicron outbreaks.
    PLoS One. 2024;19:e0299844.
    

    >> Share

    
    
30. SENOO-DOGBEY VE, Anto F, Quansah R, Danso-Appiah A, et al
    Completion of three-dose hepatitis B vaccination cycle and associated factors among health care workers in the Greater Accra Region of Ghana.
    PLoS One. 2024;19:e0298771.
    

    >> Share

    
    
31. O'KENNEDY MM, Roth R, Ebersohn K, du Plessis LH, et al
    Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice.
    PLoS One. 2024;19:e0301340.
    

    >> Share

    
    
32. CHISTY ZA, Li DD, Haile M, Houston H, et al
    Immune response kinetics to SARS-CoV-2 infection and COVID-19 vaccination among nursing home residents-Georgia, October 2020-July 2022.
    PLoS One. 2024;19:e0301367.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

33. FREEDMAN AS, Sheen JK, Tsai S, Yao J, et al
    Inferring COVID-19 testing and vaccination behavior from New Jersey testing data.
    Proc Natl Acad Sci U S A. 2024;121:e2314357121.
    

    >> Share

    
    
34. CHEN G, Han Q, Li WX, Hai R, et al
    Live-attenuated virus vaccine defective in RNAi suppression induces rapid protection in neonatal and adult mice lacking mature B and T cells.
    Proc Natl Acad Sci U S A. 2024;121:e2321170121.
    

    >> Share

    
    

    
    Science

35. COHEN J
    Plans to expand African vaccine production face steep hurdles.
    Science. 2024;384:254-255.
    

    >> Share

    
    
36. KUNJAPUR AM
    Planting a chemical flag on antigens.
    Science. 2024;384:41-42.
    

    >> Share

    
    

    
    Vaccine

37. INGRAO F, Ngabirano E, Rauw F, Dauphin G, et al
    Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken.
    Vaccine. 2024 Apr 18:S0264-410X(24)00452-3. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
38. WON H, Kim JA, Jeong NY, Choi NK, et al
    Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly.
    Vaccine. 2024 Apr 18:S0264-410X(24)00400-6. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
39. RICKE IJ, Spaulding AB, Rajtar NN, Benton EM, et al
    Predictors of willingness to receive updated 2023-2024 COVID-19 booster vaccines among a convenience sample in Minnesota.
    Vaccine. 2024 Apr 18:S0264-410X(24)00480-8. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
40. ORANGZEB S, Desalegn A, Trinh NTH, Zhao J, et al
    COVID-19 vaccine uptake among children and adolescents in Norway: A comprehensive registry-based cohort study of over 800,000 individuals.
    Vaccine. 2024 Apr 18:S0264-410X(24)00464-X. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
41. GAJEWSKA M, Lewtak K, Gorynski P, Piotrowicz M, et al
    Effect of the PCV 10 vaccination on community-acquired pneumonia hospitalisations after four years of its introduction into the Polish National Immunisation Programme: Follow-up study.
    Vaccine. 2024 Apr 18:S0264-410X(24)00433-X. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
42. BEITARI S, Yi S, Sharma S, Yung R, et al
    Exploring COVID-19 vaccine uptake and hesitancy among vulnerable populations in inner city Vancouver, Canada: Insights into characteristics and clinical outcomes.
    Vaccine. 2024 Apr 17:S0264-410X(24)00477-8. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
43. MUTSAERTS EAML, van Cranenbroek B, Madhi SA, Simonetti E, et al
    Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones.
    Vaccine. 2024 Apr 17:S0264-410X(24)00448-1. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
44. MATUR RV, Thuluva S, Gunneri S, Yerroju V, et al
    Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
    Vaccine. 2024 Apr 17:S0264-410X(24)00362-1. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
45. JI Y, Sui X, Miao W, Wang C, et al
    Erratum to "Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model" [Vaccine 42(6) (2024) 1292-1299].
    Vaccine. 2024 Apr 16:S0264-410X(24)00386-4. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
46. PEREIRA ET, Iasulaitis S, Greco BC
    Analysis of causal relations between vaccine hesitancy for COVID-19 vaccines and ideological orientations in Brazil.
    Vaccine. 2024 Apr 16:S0264-410X(24)00436-5. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
47. GEE J, Shimabukuro TT, Su JR, Shay D, et al
    Overview of U.S. COVID-19 vaccine safety surveillance systems.
    Vaccine. 2024 Apr 16:S0264-410X(24)00224-X. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
48. LEE N, Hong Y, Kirkpatrick CE, Hu S, et al
    COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants.
    Vaccine. 2024 Apr 16:S0264-410X(24)00402-X. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
49. DEAL A, Crawshaw AF, Salloum M, Hayward SE, et al
    Understanding the views of adult migrants around catch-up vaccination for missed routine immunisations to define strategies to improve coverage: A UK in-depth interview study.
    Vaccine. 2024 Apr 16:S0264-410X(24)00406-7. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
50. VAN DER POL S, Zeevat F, Postma MJ, Boersma C, et al
    Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations.
    Vaccine. 2024 Apr 17:S0264-410X(24)00465-1. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
51. SHEFFER R, Bucris E, Amitai Z, Indenbaum V, et al
    Measles outbreak associated with a preschool setting among partially vaccinated children in the Tel Aviv District, Israel, October 2023.
    Vaccine. 2024 Apr 15:S0264-410X(24)00427-4. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
52. MELNIKOW J, Padovani A, Zhang J, Miller M, et al
    Patient concerns and physician strategies for addressing COVID-19 vaccine hesitancy.
    Vaccine. 2024 Apr 15:S0264-410X(24)00437-7. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
53. WONG IOL, Wong C, Mak N, Dai A, et al
    Assessment of the impact of the vaccine pass policy on COVID-19 vaccine hesitancy and uptake among Chinese adults in Hong Kong.
    Vaccine. 2024 Apr 15:S0264-410X(24)00449-3. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
54. MOHANTY S, Done N, Liu Q, Song Y, et al
    Incidence of pneumococcal disease in children
    Vaccine. 2024;42:2758-2769.
    

    >> Share

    
    
55. HILL-BATORSKI L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, et al
    Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
    Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
56. WANG Y, Xu F, Yuan C, Zhang Y, et al
    Comparison of immune effects of porcine circovirus type 2d (PCV2d) capsid protein expressed by Escherichia coli and baculovirus-insect cells.
    Vaccine. 2024;42:2848-2857.
    

    >> Share

    
    
57. OWUSU-EDUSEI K, Favre-Bulle A, Tsoumani E, Mutschler T, et al
    Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
    Vaccine. 2024 Apr 11:S0264-410X(24)00431-6. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
58. AHERN S, Browne J, Murphy A, Teljeur C, et al
    An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
    Vaccine. 2024 Apr 11:S0264-410X(24)00441-9. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
59. YONEKAWA M, Watanabe T, Kogawara O, Yoshii C, et al
    Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and older.
    Vaccine. 2024 Apr 12:S0264-410X(24)00388-8. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
60. NASKAR S, Harsukhbhai Chandpa H, Agarwal S, Meena J, et al
    Super epitope dengue vaccine instigated serotype independent immune protection in-silico.
    Vaccine. 2024 Apr 13:S0264-410X(24)00423-7. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
61. BAKER J, Aliabadi N, Munjal I, Jiang Q, et al
    Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Vaccine. 2024 Apr 13:S0264-410X(24)00387-6. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
62. SUKIK L, Chemaitelly H, Ayoub HH, Coyle P, et al
    Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.
    Vaccine. 2024 Apr 13:S0264-410X(24)00440-7. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
63. YAGI A, Ueda Y, Kimura T
    HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives.
    Vaccine. 2024 Apr 13:S0264-410X(24)00407-9. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
64. DAVIS BM, Blake I, Panicker G, Meites E, et al
    Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9-14 years at 5 years after vaccination.
    Vaccine. 2024 Apr 15:S0264-410X(24)00447-X. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    

    
    Virus Res

65. AVIZINIENE A, Dalgediene I, Armalyte J, Petraityte-Burneikiene R, et al
    Immunogenicity of Novel vB_EcoS_NBD2 Bacteriophage-Originated Nanotubes as a Carrier for Peptide-Based Vaccines.
    Virus Res. 2024 Apr 11:199370. doi: 10.1016/j.virusres.2024.199370.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share